Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
D. Halpin, E. Bateman, P. Paggiaro, E. Bleecker, M. Engel, P. Moroni-Zentgraf, H. Schmidt, H. Kerstjens (Exeter, United Kingdom; Cape Town, South Africa; Pisa, Italy; Winston-Salem, United States Of America; Ingelheim am Rhein, Biberach an der Riss, Germany; Groningen, Netherlands)
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Session: New clinical evidence for asthma and COPD treatments
Session type: Thematic Poster Session
Number: 2427
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Halpin, E. Bateman, P. Paggiaro, E. Bleecker, M. Engel, P. Moroni-Zentgraf, H. Schmidt, H. Kerstjens (Exeter, United Kingdom; Cape Town, South Africa; Pisa, Italy; Winston-Salem, United States Of America; Ingelheim am Rhein, Biberach an der Riss, Germany; Groningen, Netherlands). Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma. Eur Respir J 2014; 44: Suppl. 58, 2427
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: